Advertisement

Topics

AstraZeneca, Merck get FDA approval for expanded use of ovarian cancer drug

06:36 EDT 21 Aug 2017 | Pharmaceutical Business Review

AstraZeneca and Merck have secured approvals from The US Food and Drug Administration (FDA) to expand the indication for their newly formulated Lynparza to cover a broader group of women suffering from ovarian cancer.

Original Article: AstraZeneca, Merck get FDA approval for expanded use of ovarian cancer drug

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca, Merck get FDA approval for expanded use of ovarian cancer drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...